Michael Anstey

Michael is a Partner specialising in life sciences investments.

Michael is a Partner specialising in life sciences investments at Cambridge Innovation Capital (CIC). Michael manages CIC's investments in Nuclera, Bicycle Therapeutics (NASDAQ: BCYC), Epitopea, TRIMTech Therapeutics, Immutrin, Congenica, and Start Codon.

Before joining CIC he was a Principal in the Health Care Practice Area at The Boston Consulting Group. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan. Prior to BCG, Michael was an Investment Analyst at Oxford Capital Partners.

Michael was also co-founder of an early-stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease.

Michael earned his DPhil in Zoology in the field of neurobiology from the University of Oxford.

He is also a co-founder of Innovate Cambridge.

Portfolio

Current companies 

View all

Bicycle Therapeutics

A new approach to precision-guided therapies

Read More

Congenica

Clinically actionable insights from patient genomes

Read More

Epitopea

Bringing cancer vaccines out of the dark

Read More

STORM Therapeutics

First-in-class therapies targeting RNA modifying enzymes

Read More

Team

Other team members

Sorry, no posts matched your criteria.